Core Insights - Protara Therapeutics (TARA) maintains optimism regarding its bladder cancer pipeline, which aims to address specific drug shortages in the non-metastatic setting and explore a novel indication [1] Company Analysis - The company is focused on developing treatments for bladder cancer, particularly in non-metastatic cases, which may present a significant market opportunity due to existing drug shortages [1] Industry Context - The analysis emphasizes the importance of understanding the science behind biotech investments, highlighting the need for thorough due diligence in this sector [1]